

Background On The Acquired Compounds

CPZEN-45 from Microbial Chemistry Research Foundation

Microbial Chemistry Research Foundation (MCRF), headquartered in Tokyo, was established to conduct microbial and microbiological research aimed at the discovery of new substances beneficial in the prevention and treatment of disease. It strives to contribute to public health and welfare by promoting the development and the utilization of these beneficial substances, and by supporting advanced academic research.

In recent years, MCRF has conducted extensive research in genomics, proteomics, cell-omics, and biological informatics technology. While continuing to search for new human medicines, it has expanded its focus to include veterinary and agricultural drugs, diagnostic substances, chemical reagents, and methodological techniques.

MCRF was the original inventor of Kanamycin, one of the first antibiotics developed for TB 50 years ago. Income from this antibiotic generated funding for MCRF's successful development of at least two macrolides, bleomycin, and other oncolytics.

MCRF has now discovered CPZEN-45, an early stage clinical candidate for treatment of TB with a new mechanism of action which was donated to the Initiative for further development. The specificity of CPZEN-45 for mycobacteria, its activity against multidrug-resistant TB, its synergistic or additive effect with other antitubercular compounds, and its lack of toxicity in preliminary studies in animals make this compound an appealing candidate for further development.

Novel Class of TB Compounds from Summit plc

Summit plc (LSE: SUMM) is a leading UK biotechnology company with a broad preclinical and clinical pipeline. Summit uses its scientific expertise to target orphan diseases, neuro-disorders and infectious diseases. The company is developing multiple drug programs that target unmet medical needs.

Underpinning Summit's drug pipeline are two innovative technology platforms: carbohydrate chemistry and zebrafish biology. These platforms support existing programs and also will be the source of future programs to replenish Summit's drug pipeline.

Summit has state of the art facilities in Oxfordshire and Aberystwyth with a specialist carbohydrate chemistry subsidiary, Dextra Laboratories, located in Reading. The company is listed on the alternative investment market (AIM) of the London Stock Exchange.

Summit's TB program is based on a novel class of compounds that has shown excellent in vitro activity against *Mycobacterium tuberculosis*, the bacteria that causes TB. The compounds act via a mode of action distinct from all other TB therapies. Significantly, the compounds are active against both multidrug-resistant bacterial strains and the dormant form of the bacteria, emphasizing their potential ability to shorten treatment regimes (a key issue with current therapies) and as a treatment for latent TB infection.